Ketamine for Methamphetamine Use Disorder (KMD)

This randomised, double-blind, placebo-controlled trial (n=120) will study the efficacy of intravenous (IV) ketamine versus IV midazolam in treating adults with moderate to severe methamphetamine use disorder (MUD).

Conducted by the University of Texas Southwestern Medical Center, this 12-week trial involves administering either IV ketamine (0.50 mg/kg) or IV midazolam (0.02 mg/kg) over 40 minutes for a total of eight infusions across six weeks. Participants will also attend weekly medical management sessions and cognitive behavioural therapy (CBT) sessions.

The primary aim is to determine if IV ketamine is superior to midazolam in reducing methamphetamine use, with additional assessments for safety and adherence to treatment.

Topic Opioid Use Disorder Addiction
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Texas
The University of Texas is conducting research with psychedelics across locations in Houston, Austin, Dallas and San Antonio.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.